Pharma BD Deal Intelligence
A foundational bioprocessing bet that reshaped Danaher itself—Pall's $13.6B acquisition was significant enough to trigger the 2016 Fortive spinoff, re-centering Danaher on life sciences. Pall rode pandemic-era filtration demand through 2021, though post-COVID destocking hit hard (bioprocess revenue down ~20% in Q3 2023).
BioPharma-Reporter (citing analyst commentary) suggested the rumored Pall deal could spark a wider M&A flurry across bioprocess tools, anticipating subsequent…
Seeking Alpha note: Evercore ISI's Ross Muken described filtration and separations as 'highly attractive,' with appealing reach in high-growth markets and…
BioProcess Insider's retrospective: combining Pall (acquired 2015) with Cytiva (acquired 2019) created a ~$7.5B-revenue bioprocess juggernaut — validating the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Danaher acquired Pall Corporation for approximately $13.6B in cash, expanding bioprocess filtration and life sciences tools platform. Pall later combined with Beckman/Leica/SCIEX/Molecular Devices to form Danaher's life sciences segment, which spun off as Veralto/Envista components. Borderline pharma BD — included as platform/diagnostics-level life sciences.
Assessment window: 5yr post-close.
$13.8B Total enterprise value of acquisition ($13.8B inc. assumed debt)
Bioprocess filtration and separation technologies are the consumables and hardware (depth filters, tangential flow filtration, single-use assemblies, chromatography media) used by biopharma manufacturers to clarify, purify and sterilize biologic drugs — monoclonal antibodies, vaccines, gene and cell therapies. Demand is driven by biologics manufacturing volume, the shift to single-use systems and rising biosimilar production. The challenge is that these are mission-critical, regulated consumables where switching costs are very high and capacity expansion lags biologics demand cycles.
Pre-deal, the bioprocess filtration and life-sciences tools landscape was an oligopoly led by Merck KGaA (post-Millipore acquisition 2010), GE Healthcare Life Sciences (which Danaher would buy in 2019 and rebrand Cytiva), Sartorius Stedim Biotech, Pall Corporation and Thermo Fisher Scientific. Danaher's $13.8B Pall acquisition (announced May 13, 2015; closed Aug 31, 2015) made Danaher's life-sciences platform the second-largest bioprocess tools player and set up the 2019 GE Biopharma deal that combined Pall + Cytiva into a roughly $7.5B-revenue 'bioprocess juggernaut'. Evercore ISI's Ross Muken called the filtration/separations market 'highly attractive' with substantial long-term margin expansion runway. The deal also catalyzed the 2016 Fortive industrial spin-off, sharpening Danaher's life-sciences focus, and pressured competitors to consolidate (Sartorius' subsequent BIA Separations and Albumedix bolt-ons).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Danaher Corporation / Pall Corporation (this deal) | 2015 | $13.6B | 77 |
| Danaher Corporation / Abcam PLC | 2023 | $5.7B | 77 |
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) | 2019 | $21.4B | 76 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
← Browse all deals · How we score deals
More: 2015 deals · Danaher Corporation deals · Other deals